Cargando…

The Role of Serum Levels of Neurofilament Light (NfL) Chain as a Biomarker in Friedreich Ataxia

Detalles Bibliográficos
Autores principales:	Frempong, Bernice, Wilson, Robert B., Schadt, Kimberly, Lynch, David R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7960909/ https://www.ncbi.nlm.nih.gov/pubmed/33737864 http://dx.doi.org/10.3389/fnins.2021.653241

Ejemplares similares

NfL and pNfH are increased in Friedreich’s ataxia
por: Hayer, Stefanie Nicole, et al.
Publicado: (2020)

Neurofilament light (NfL) as biomarker in serum and CSF in status epilepticus
por: Margraf, Nils G., et al.
Publicado: (2023)

Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1)
por: Nicoletti, Tommaso F., et al.
Publicado: (2022)

Friedreich Ataxia: Multidisciplinary Clinical Care
por: Lynch, David R, et al.
Publicado: (2021)

Editorial: The Impact of Neurofilament Light Chain (NFL) Quantification in Serum and Cerebrospinal Fluid in Neurodegenerative Diseases
por: Zanella, Isabella, et al.
Publicado: (2022)

Neurofilament Light Chain (NfL) in Blood—A Biomarker Predicting Unfavourable Outcome in the Acute Phase and Improvement in the Late Phase after Stroke
por: Pekny, Milos, et al.
Publicado: (2021)

NEUROFILAMENT LIGHT CHAIN (NFL) AND GENERAL COGNITIVE ABILITY IN ADULTS APPROACHING MIDLIFE
por: Reynolds, Chandra, et al.
Publicado: (2022)

Neurofilament Light Chain Is a Biomarker of Neurodegeneration in Ataxia Telangiectasia
por: Donath, H., et al.
Publicado: (2021)

Neurofilament light chain is a promising serum biomarker in spinocerebellar ataxia type 3
por: Li, Quan-Fu, et al.
Publicado: (2019)

Friedreich Ataxia and nephrotic syndrome: a series of two patients
por: Shinnick, Julianna E., et al.
Publicado: (2016)

SARS-CoV-2 in patients with Friedreich ataxia
por: Shen, Megan M., et al.
Publicado: (2022)

Plasma Neurofilament Light (NfL) in Patients Affected by Niemann–Pick Type C Disease (NPCD)
por: Dardis, Andrea, et al.
Publicado: (2021)

Serum neurofilament light chain as a severity marker for spinocerebellar ataxia
por: Shin, Hye-Rim, et al.
Publicado: (2021)

FXN gene methylation determines carrier status in Friedreich ataxia
por: Lam, Christina, et al.
Publicado: (2023)

Identification of a novel missense mutation in Friedreich's ataxia –FXN(W) (168R)
por: Clark, Elisia, et al.
Publicado: (2019)

Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3
por: Garcia‐Moreno, Hector, et al.
Publicado: (2022)

Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model
por: Dreger, Marie, et al.
Publicado: (2021)

Friedreich's Ataxia
por: Anderson, J. Wallace
Publicado: (1893)

Predictors of loss of ambulation in Friedreich's ataxia
por: Rummey, Christian, et al.
Publicado: (2020)

IMMU-02. CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL NEUROTOXICITY CORRELATES WITH PRETREATMENT AND ACUTE CSF NEUROFILAMENT LIGHT CHAIN (NFL) LEVELS
por: Gust, Juliane, et al.
Publicado: (2020)

Progression of Friedreich ataxia: quantitative characterization over 5 years
por: Patel, Maya, et al.
Publicado: (2016)

The Pathology of Friedreich's Ataxia
por: Rainy, Harry
Publicado: (1905)

Neuroinflammation in Friedreich’s Ataxia
por: Apolloni, Savina, et al.
Publicado: (2022)

NfL as a biomarker for neurodegeneration and survival in Parkinson disease
por: Bäckström, David, et al.
Publicado: (2020)

Consensus clinical management guidelines for Friedreich ataxia
por: Corben, Louise A, et al.
Publicado: (2014)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
por: Gisslén, Magnus, et al.
Publicado: (2015)

Serum neurofilament light chain is a useful biomarker in pediatric multiple sclerosis
por: Reinert, Marie-Christine, et al.
Publicado: (2020)

Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression
por: Mollenhauer, Brit, et al.
Publicado: (2020)

Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy
por: van Ballegoij, Wouter J. C., et al.
Publicado: (2020)

Frataxin levels in peripheral tissue in Friedreich ataxia
por: Lazaropoulos, Michael, et al.
Publicado: (2015)

Is Friedreich ataxia an epigenetic disorder?
por: Kumari, Daman, et al.
Publicado: (2012)

The Pathogenesis of Cardiomyopathy in Friedreich Ataxia
por: Koeppen, Arnulf H., et al.
Publicado: (2015)

Depressive symptoms in Friedreich ataxia
por: Nieto, Antonieta, et al.
Publicado: (2018)

Heart disease in Friedreich’s ataxia
por: Hanson, Emily, et al.
Publicado: (2019)

Drug Repositioning in Friedreich Ataxia
por: Rufini, Alessandra, et al.
Publicado: (2022)

Two Cases of Friedreich’s Ataxia
por: Stephenson, F. H.
Publicado: (1897)

Respiratory Function in Friedreich’s Ataxia
por: Vinante, Elena, et al.
Publicado: (2022)

Longitudinal analysis of contrast acuity in Friedreich ataxia
por: Hamedani, Ali G., et al.
Publicado: (2018)

Central Nervous System Therapeutic Targets in Friedreich Ataxia
por: Harding, Ian H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_34ehc94g6ata2ihfcobdrkoljq